feed,title,long_url,short_url
Benzinga,Salarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal,https://benzinga.com/general/biotech/22/01/25035454/salarius-plans-to-enter-15b-protein-degradation-space-with-deuterx-deal,https://j.mp/3rfz3uT
Benzinga,VYNE Therapeutics Offloads Its Topical Minocycline Assets To Journey Medical In $450M+ Deal,https://benzinga.com/general/biotech/22/01/25034008/vyne-therapeutics-offloads-its-topical-minocycline-assets-to-journey-medical-in-450m-deal,https://j.mp/3zXsiSd
